Peripheral Spondyloarthritis Market

Peripheral Spondyloarthritis Market Outlook (2024 to 2034)

The global peripheral spondyloarthritis market was valued at US$ 2,503.2 million in 2023 and has been forecasted to expand at a noteworthy CAGR of 6.8% to end up at US$ 5,220.7 million by 2034.

The peripheral spondyloarthritis is one of the type of autoimmune disease. The peripheral spondyloarthritis market is associated with diagnosis and treatment of several type of arthritic diseases such as reactive arthritis, psoriatic arthritis, enteropathic arthritis, and other undifferentiated peripheral spondyloarthritis.

The other aspects refer to disease with peripheral joints, predominantly entheses or the areas where tendons and ligaments insert into bones. It is associated with intense pain, swelling and damage to the joint if not get treated. Since the disease is chronic and progressive in nature there is a decrease in quality of life. Early diagnosis and subsequent therapy is crucial for long term management of affected individuals.

This huge growth in the market during the last decade is because of increased awareness, early diagnostic technologies, and the advent of biologics and DMARDs. Nowadays, treatments are experiencing fast evolution and advancements in this market. TNF inhibitors, IL-17 inhibitors, and JAK inhibitors are involved in clinical therapy of the disease with remarkable enhancing of the results of the treatment of the patient and reduction of the rate of the development of irreversible destructive changes in the joints.

Growing incidence of autoimmune diseases across the world is also projected to boost demand for better therapeutic solutions and diagnostic solutions in peripheral spondyloarthritis market. Major leading regions, such as North America-leading the United States and Western Europe-majorly Germany and France-are expected to retain their dominance in this market due to better healthcare and continuous clinical research.

Report Attributes	Details
Peripheral Spondyloarthritis Market Size (2023A)	US$ 2,503.2 Million
Estimated Market Value (2024E)	US$ 2,704.0 Million
Forecasted Market Value (2034F)	US$ 5,220.7 Million
Global Market Growth Rate (2024-2034)	6.8% CAGR
Western Europe Market Share (2024)	22.4%
France Market Growth Rate (2024-2034)	6.9% CAGR
Key Companies Profiled	AbbVie; Novartis; Pfizer; UCB Pharma; Janssen Biotech; Amgen; Bristol-Myers Squibb; Eli Lilly; Others

Historic Analysis (2019 to 2023) and Future (2024 to 2034) Pathway Analysis for the Peripheral Spondyloarthritis Market

The market for peripheral spondyloarthritis grew at a growth rate of 6.1% from 2019 to 2023, and by the end of 2023, it was valued at US$ 2,503.2 million. There were stable increments in this market as the conditions popularity was on the rise and patients required more sophisticated biologic therapy such as TNF inhibitors. This had been help by better diagnosis, improved patient awareness and use of individualized medication. High treatment costs and disparities in access to care restrained growth in some areas.

Historical Report Attributes	Details
Market Size (2019A)	US$ 1,946.1 million
Market Size (2023A)	US$ 2,503.2 million
Historical CAGR (2019-2023)	6.1%
Forecasted CAGR (2024-2034)	6.8%

• Short Term (2024 to 2028): The market is expected to show strong growth with innovation for JAK inhibitors and IL-17 inhibitors. Better access within the emerging economies, advancement in liquid biopsies for diagnosis, and awareness are likely to spark growth. Increased regulatory approvals along with the therapeutic adoption of these will also add steam to the market growth.
• Medium Term (2028 to 2030): Growth continues to stabilize, with saturation in the developed markets offset by further growth in Asia-Pacific and Latin America. The technologies are expected to be further supported by technological innovations, such as AI-driven diagnostics. Pricing pressures due to biosimilars may affect revenues in mature markets, but overall adoption of biologics remains strong.
• Long Term (2030 to 2034): The market reaches maturity, characterized by deep market penetration of novel therapies such as multiplex biomarker assays. For emerging markets, expanding access to healthcare and new combination therapies are the major drivers. Integration of digital health monitoring tools and telemedicine in providing sustained growth focuses on patient-centric treatment options.

On the back of the aforementioned facts, the peripheral spondyloarthritis market is anticipated to grow at a CAGR of 6.8% during the forecast period from 2024-2034, according to the Fact.MR, a market research and competitive intelligence provider.

Market Dynamics

What are the Factors Propelling Peripheral Spondyloarthritis Market Globally?

“Advancements in biologics and targeted therapies”

The treatment of peripheral spondyloarthritis has been revolutionized by biologic and targeted therapies, making them the cornerstone in the market's growth. Medications like TNF inhibitors, which include etanercept and infliximab, among others, have greatly improved patient outcomes by acting on basic inflammatory pathways to decrease pain and stiffness in the joints and delay disease progression. The success of these agents has promoted further innovation, including the approval of IL-17 inhibitors, secukinumab and ixekizumab, providing another mechanism of action for patients resistant to traditional biologics.

The newer class of targeted therapies includes JAK inhibitors, further extending the scope. These oral drugs thus offer a very viable alternative for those patients who prefer non-injectable therapies, while their capacity for modulating multiple inflammatory pathways improves their efficacy. The increasing clinical trial success rate, regulatory approvals, and real-world evidence supportive of the long-term benefits of biologics and JAK inhibitors are significant adoption drivers.

These biologic therapies see increasing demand due to their effectiveness, aided by reimbursement programs in developed nations and increased access to healthcare in emerging markets. With continued reductions in the cost of biosimilars, this availability should continue to increase in the management of peripheral spondyloarthritis.

“Improved diagnostic technologies contributing to earlier and more accurate detection”

Overlapping symptoms with other conditions usually led to misdiagnosis via the traditional modes of diagnosis. However, the discovery of immunohistochemistry, flow cytometry, and genomic profiling has identified a specific set of biomarkers and inflammatory pathways associated with peripheral spondyloarthritis that gives enhanced diagnostic precision.

This includes AI-powered pathology tools and digital imaging systems that support not only a more effective identification of disease subtypes but also improve diagnostic workflows. Technologies such as liquid biopsies offer increasingly successful means of non-invasive diagnostics for circulating biomarkers, serving early diagnosis and treatment monitoring. Furthermore, multiplex assays allow an increasingly simultaneous analysis of multiple biomarkers to shorten the diagnosis time with the objective of enabling personalized treatment plans.

Investments in research and development studies, has also strengthen this trend. With greater awareness about peripheral spondyloarthritis among the general population worldwide, the demand for effective and time-saving diagnostic tools is likely to rise and would considerably affect the course of the market.

What are the Challenges Encountered by Market Players in Peripheral Spondyloarthritis Market?

“High cost associated with biologics therapy and risk of misdiagnosis may limit the peripheral spondyloarthritis market”

The major limitation to the peripheral spondyloarthritis market is the high cost of treatment using biologics and the chances of misdiagnosis. It is worth noting that the therapies include TNF inhibitors, JAK inhibitors, and IL-17 inhibitors which come with relatively high cost meaning that they may not easily be adopted in the developing / low and middle-income countries. As pointed out earlier, even in the modern world, public health programs and insurance companies cover the cost that inevitably limits broad use.

Peripheral spondyloarthritis on the other hand is a very complex and also heterogeneous; therefore, it has very high chances of being misdiagnosed. Presymptomatic disease symptoms are also one of the reasons for the late and / or incorrect diagnosis of other rheumatic and autoimmune connective diseases, including rheumatoid arthritis and fibromyalgia.

To the contrary, without such diagnostic equipment and personnel, misdiagnosis is so much common, in less resourced part of the world. Such diagnostic hurdles to timely diagnosis have a negative impact on patients’ prognosis and limit the likelihood of general market expansion. Indeed, for the continual growth of the peripheral spondyloarthritis market, these barriers must be addressed.

Country-wise Insights

Why Adoption of Peripheral Spondyloarthritis is high in the United States?

“Strong research & development ecosystem with high awareness & diagnosis rate is driving market for peripheral spondyloarthritis in U.S.”

The market in the United States is estimated at US$ 813.0 million in 2024 and is projected to expand at a CAGR of 6.9% through 2034. This market is projected to generate a US$ 772.6 million absolute opportunity from 2024 to 2034.

High awareness of disease and diagnosis capabilities coupled with advanced research and development environment lead to development of peripheral spondyloarthritis market in United States. The U.S. has a large number of biologics and small molecules in its pipeline in development with the efforts of major key players like AbbVie, Amgen, and Eli Lilly. These firms are spending heavily on clinical trials, in search of better solutions as JAK inhibitors and IL-17 inhibitors. The strong R&D provides a boost to the accelerated approval of drugs, ensuring that advanced treatment options enter the healthcare system in time.

Besides this, awareness campaigns and education on the part of government agencies such as the CDC (Centers for Disease Control and Prevention), and patient advocacy groups, raise the degree of recognition of symptoms of peripheral spondyloarthritis among both providers and patients. This leads to more early and accurate diagnoses, an important component in effective disease management. Advanced diagnostic facilities such as flow cytometry, genetic profiling, and AI-enhanced imaging technologies support this trend. With high insurance coverage and reimbursement policies that ease the financial burden caused by biologic treatments, further ensures access to advanced therapies.

Why is Germany a Lucrative Market for Peripheral Spondyloarthritis?

“Increasing aging population and disease prevalence contributed with strong healthcare infrastructure are making Germany a lucrative market”

The market in the Germany is estimated to reach US$ 353.1 million in 2034 at a CAGR of 6.8%. This market is projected to generate a US$ 170.1 million absolute opportunity from 2024 to 2034.

Autoimmune diseases such as peripheral spondyloarthritis are most often noted in people of increasing age, growth in the number of elderly individuals in Germany increases demand for effective diagnostic tools and advanced therapies like biologics and JAK inhibitors.

This is further supported by the strong structure of German healthcare, which ensures access to innovative therapies and diagnostics for large sections of the population. Wide insurance coverage allows a major part of the population to access novel therapies, which in turn leads to better patient outcomes and thereby increases market adoption. Specialized rheumatology clinics and medical institutions enable quality care, thereby leading to early diagnosis and management of peripheral spondyloarthritis.

Additionally, heavy investment by the government in healthcare and German leadership in pharmaceutical innovation and clinical research contribute to more advanced options for treatment. All these factors combined render Germany a very important market for diagnosis and treatment related to peripheral spondyloarthritis.

Category-wise Insights

Which Treatment Type are Expected to See Most Growth in Peripheral Spondyloarthritis Market?

“The proven efficacy of disease-modifying antirheumatic drugs (DMARDs) leads to its highest growth in peripheral spondyloarthritis market”

Demand for disease-modifying antirheumatic drugs (DMARDs) is expected to generate an absolute dollar opportunity of US$ 1,068.0 million. DMARDs such as low-dose methotrexate, sulfasalazine is being employed conventionally in the management of this disease, however biologic DMARDs including TNF inhibitors and IL-17 inhibitors are also getting attraction because of their effectiveness in controlling inflammation and halting further joint degradation. This shows that the tendencies towards usage of biologic DMARDs are actively rising as they guarantee accrued therapeutic impact and lesser side effects compared with conventional DMARDs.

New developments in oral preparations including JAK inhibitors have made the topical DMARDs more attractive through introduction of non-invasive and easily administrating DMARDs. Growing knowledge base of healthcare practitioners & patients on long-term advantages of early use of DMARDs result in increased usage of DMARD drugs.

This has been even more boosted with changes in healthcare accessibility, reimbursement policies as well as advanced clinical development on DMARD therapy hence making the segment one of the most important in the market.

Competitive Landscape

Key competitors in the peripheral spondyloarthritis market are AbbVie, Novartis, Pfizer, UCB Pharma, Janssen Biotech, Amgen, Bristol-Myers Squibb, and Eli Lilly among others.

These players are concentrating on developing newer, advanced biologic and DMARD therapies. The leading companies, such as AbbVie, Novartis, and Amgen, have gained a forefront in developing newer therapies that include TNF inhibitors and JAK inhibitors, associated with strategic activities such as clinical trials, product diversification, and increasing market access for patients across the globe. In addition to this, strategic collaborations and partnerships with research organizations further develop their pipelines and solidify their presence in the market.

• In September 2024, USFDA approved UCB’s BIMZELX® (bimekizumab-bkzx) for the treatment of adults with active psoriatic arthritis (PsA), adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation, and adults with active ankylosing spondylitis (AS). It is a first approved treatment for these three indications that is designed to selectively inhibit two key cytokines driving inflammatory processes – interleukin 17A (IL-17A) and interleukin 17F (IL-17F)
• In November 2023, Janssen Pharmaceuticals, Inc. released new data from three clinical trials supporting established efficacy of TREMFYA in key psoriatic domains across those who were bio-naïve or TNFi-experienced. TREMFYA is the first and only fully human selective interleukin (IL)-23p19-subunit inhibitor therapy approved for the treatment of adults living with active PsA.

Fact.MR has provided detailed information about the key players in peripheral spondyloarthritis positioned across regions, current research in this market, recent key developments, epidemiological analysis, sales growth, and speculative technological expansion, in the recently published report.

Segmentation of Peripheral Spondyloarthritis Industry Research

• By Treatment Type :

  • Disease-modifying antirheumatic Drugs (DMARDs)
  • Non-steroidal Anti-inflammatory Drugs (NSAIDs)
  • Corticosteroids
  • Janus kinase (JAK) Inhibitors

• By Type of Disease :

  • Psoriatic Arthritis
  • Reactive Arthritis
  • Enteropathic Arthritis
  • Undifferentiated Peripheral Spondyloarthritis

• By End User :

  • Hospitals & Clinics
  • Homecare Settings
  • Outpatient Centers

• By Region :

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • East Asia
  • South Asia & Pacific
  • Middle East & Africa